ARCHIVES

Phase III Five-Year Data Show Erbitux Increases Survival Of Head And Neck Cancer

This article is from The Cancer Letter archive.

Vol. 31 No. 9 | September 26, 2008

Download PDF Visit The Full Archive

Related Articles

Schilskly Promoted to Associate Dean At Chicago, Vogelzang To Direct Center

March 5, 1999

Ovarian Cancer Screening Unnecessary for Most Women, Consensus Panel Says

April 15, 1994

NCI Hires Harold Freeman To Direct New Center For Study Of Health Disparities.

June 16, 2000

ODAC Votes Against Adria’s Chemoprotector, Okays Leustatin

July 3, 1992

Bill Pressures HCFA To Launch Project On Reimbursement for Cancer Trials

July 26, 1996

FDA News: ODAC Recommends Taxol For KS; Votes Against 2 Other Drugs

July 4, 1997